4D Molecular Therapeutics Reports Positive Interim Phase 1 Results for 4D-710 in Cystic Fibrosis
I'm PortAI, I can summarize articles.
4D Molecular Therapeutics announced positive interim Phase 1 results for 4D-710 in treating cystic fibrosis lung disease. The drug was well tolerated, showed relevant CFTR expression levels, and improved lung function and quality of life. Phase 2 enrollment is expected to complete in early 2026, with updates later that year. The data was presented in a webcast on December 17, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments